Replies to post #1508 on IDM Pharma, Inc. (IDMI)

[meixatech]

Bow,

Thanks for your analysis. I am a scientist which means that my focus has been on the science and not the technicals of the company. Years ago with IDMI’s predecessor company, EPMN, I was totally blown away with EP-2101 (now IDM-2101). What an extraordinary feat of not only molecular engineering, but immunology! The potential of IDM-2101 in cancer treatment cannot be overstated. Indeed, at the last shareholder’s meeting, a director stated to me that the real jewel of IDMI is not Mepact, but IDM-2101. It is with IDM-2101 where the value of IDMI lies.

The core strategy of IDMI has not been stated. I believe that Mepact, which is also a drug to activate the immune system against cancer, was always considered by CEO Walbert a “proof of concept” for the technology which activates a patient’s immune system against cancer. IDM-2101 is vastly superior to Mepact in this regard.

But what will be the conditions of the buyout? Will it be based on the SP a certain number of days after the approval of Mepact by the EU? Or will it be based simply on the approval itself, and the value of the buyout has been previously set? I sure hope it is the latter… because if it is, it will represent not only one of the largest discrepancies between the market value of a company and its sale price, but it will also mean my investment in IDMI will be covered.